Blood coagulation factor VIII, Blood coagulation factor IX, Blood coagulation factor XI (Factor VIII (FVIII), Factor IX (FIX), Factor XI (FXI))

The blood coagulation factors VIII, IX, and XI are essential components of the intrinsic pathway of the blood coagulation cascade, which is responsible for hemostasis (prevention of bleeding following vascular injury)[1][2][3][4][6][7]. **Factor VIII** acts as a cofactor for factor IXa, enabling the activation of factor X on phospholipid surfaces in association with calcium ions[1][2][4][6][7]. **Factor IX** is a vitamin K–dependent serine protease that, once activated (FIXa), interacts with activated FVIII (FVIIIa) to form the intrinsic tenase complex, which activates factor X[3][4][6][7]. **Factor XI** is a serine protease that, when activated (FXIa), activates factor IX, thus propagating the cascade[4][6][7]. Deficiencies in these factors cause hemophilia A (FVIII), hemophilia B (FIX), and hemophilia C (FXI), leading to bleeding disorders of varying severity[1][3][4][7]. Therapeutic strategies include replacement with recombinant or plasma-derived factors, bispecific antibodies, and gene therapy for certain types[2][3]. Safety concerns include the development of neutralizing antibodies, allergic reactions, and, in rare cases, thrombosis. Each of these factors represents an important therapeutic target both for replacement in bleeding disorders and for inhibition in thrombosis or cardiovascular disease. The canonical/clinical approach is to treat each factor as a distinct molecular entity rather than as a grouped target. **Note on correctness:** The target as named ("Blood Coagulation Factors VIII, IX, and XI") is not a standard singular molecular target but a group of three distinct factors, each with its own molecular/clinical characteristics and gene encoding. For structured mapping, they are best considered separately[1][3][4][6][7].

Other names

Factor VIII: Antihemophilic factor AAHFF8Factor IX: Christmas factorF9Factor XI: Plasma thromboplastin antecedentPTAF11

Replacement therapy: restores deficient factor activity Bypassing agents (for inhibitors): mimic or bypass FVIII/FIX function Gene therapy: endogenous synthesis of missing factor Monoclonal antibody (Emicizumab): FVIIIa mimetic activity